According to #TechSci Research report, Global Car-T Cell Therapy Market stood at USD1709.00 million in 2021 and is expected to grow at a CAGR of 64.66% during the forecast period. Gain More Insight: https://bit.ly/3en2NRL Get Sample Report: https://bit.ly/3EAW5RB Press Release: https://bit.ly/3vNi06J Website: https://www.techsciresearch.com/ Market Research News: https://techsciblog.com/

1. Global CAR-T Cell Therapy Market
FORECAST AND OPPORTUNITIES
2017 – 2027
M A R K E T I N T E L L I G E N C E . C O N S U L T I N G www.techsciresearch.com

2. 2
© TechSci Research
Table of Contents
2
S. No. Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customer
4.1. Brand Awareness
4.2. Unmet Need and Challenges
4.3. Factors Driving the CAR-T Cell Therapy Market
5. Global CAR-T Cell Therapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1.
By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus
(Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene
Vicleucel), Others)
5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
5.2.3.
By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL),
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
5.2.4. By Treatment Type (Single Treatment, Combination Treatment)
5.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
5.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
5.2.7. By Company (2021)
5.2.8. By Region
5.3. Market Map (By Product Type, By Indication, and By Region)

3. 3
© TechSci Research
Table of Contents
3
S. No. Contents
6. North America CAR-T Cell Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Tumor Type
6.2.2. By Indication
6.2.3. By Treatment Type
6.2.4. By Targeted Antigen
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States CAR-T Cell Therapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Tumor Type
6.3.1.2.2. By Indication
6.3.1.2.3. By Treatment Type
6.3.1.2.4. By Targeted Antigen
6.3.1.2.5. By End User

4. 4
© TechSci Research
Table of Contents
4
S. No. Contents
6.3.2. Canada CAR-T Cell Therapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Tumor Type
6.3.2.2.2. By Indication
6.3.2.2.3. By Treatment Type
6.3.2.2.4. By Targeted Antigen
6.3.2.2.5. By End User
6.3.3. Mexico CAR-T Cell Therapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Tumor Type
6.3.3.2.2. By Indication
6.3.3.2.3. By Treatment Type
6.3.3.2.4. By Targeted Antigen
6.3.3.2.5. By End User

5. 5
© TechSci Research
Table of Contents
5
S. No. Contents
7. Europe CAR-T Cell Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tumor Type
7.2.2. By Indication
7.2.3. By Treatment Type
7.2.4. By Targeted Antigen
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany CAR-T Cell Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tumor Type
7.3.1.2.2. By Indication
7.3.1.2.3. By Treatment Type
7.3.1.2.4. By Targeted Antigen
7.3.1.2.5. By End User

6. 6
© TechSci Research
Table of Contents
6
S. No. Contents
7.3.2. France CAR-T Cell Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tumor Type
7.3.2.2.2. By Indication
7.3.2.2.3. By Treatment Type
7.3.2.2.4. By Targeted Antigen
7.3.2.2.5. By End User
7.3.3. Switzerland CAR-T Cell Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tumor Type
7.3.3.2.2. By Indication
7.3.3.2.3. By Treatment Type
7.3.3.2.4. By Targeted Antigen
7.3.3.2.5. By End User

7. 7
© TechSci Research
Table of Contents
7
S. No. Contents
7.3.4. United Kingdom CAR-T Cell Therapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Tumor Type
7.3.4.2.2. By Indication
7.3.4.2.3. By Treatment Type
7.3.4.2.4. By Targeted Antigen
7.3.4.2.5. By End User
7.3.5. Italy CAR-T Cell Therapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Tumor Type
7.3.5.2.2. By Indication
7.3.5.2.3. By Treatment Type
7.3.5.2.4. By Targeted Antigen
7.3.5.2.5. By End User

8. 8
© TechSci Research
Table of Contents
8
S. No. Contents
7.3.6. Spain CAR-T Cell Therapy Market Outlook
7.3.6.1. Market Size & Forecast
7.3.6.1.1. By Value
7.3.6.2. Market Share & Forecast
7.3.6.2.1. By Tumor Type
7.3.6.2.2. By Indication
7.3.6.2.3. By Treatment Type
7.3.6.2.4. By Targeted Antigen
7.3.6.2.5. By End User
8. Asia-Pacific CAR-T Cell Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tumor Type
8.2.2. By Indication
8.2.3. By Treatment Type
8.2.4. By Targeted Antigen
8.2.5. By End User
8.2.6. By Country

9. 9
© TechSci Research
Table of Contents
9
S. No. Contents
8.3.1. China CAR-T Cell Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tumor Type
8.3.1.2.2. By Indication
8.3.1.2.3. By Treatment Type
8.3.1.2.4. By Targeted Antigen
8.3.1.2.5. By End User
8.3.2. Japan CAR-T Cell Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tumor Type
8.3.2.2.2. By Indication
8.3.2.2.3. By Treatment Type
8.3.2.2.4. By Targeted Antigen
8.3.2.2.5. By End User

10. 10
© TechSci Research
Table of Contents
10
S. No. Contents
8.3.3. India CAR-T Cell Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tumor Type
8.3.3.2.2. By Indication
8.3.3.2.3. By Treatment Type
8.3.3.2.4. By Targeted Antigen
8.3.3.2.5. By End User
8.3.4. Australia CAR-T Cell Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Tumor Type
8.3.4.2.2. By Indication
8.3.4.2.3. By Treatment Type
8.3.4.2.4. By Targeted Antigen
8.3.4.2.5. By End User

11. 11
© TechSci Research
Table of Contents
11
S. No. Contents
8.3.5. South Korea CAR-T Cell Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Tumor Type
8.3.5.2.2. By Indication
8.3.5.2.3. By Treatment Type
8.3.5.2.4. By Targeted Antigen
8.3.5.2.5. By End User
9. South America CAR-T Cell Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tumor Type
9.2.2. By Indication
9.2.3. By Treatment Type
9.2.4. By Targeted Antigen
9.2.5. By End User
9.2.6. By Country

12. 12
© TechSci Research
Table of Contents
12
S. No. Contents
9.3. South America: Country Analysis
9.3.1. Brazil CAR-T Cell Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1 By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tumor Type
9.3.1.2.2. By Indication
9.3.1.2.3. By Treatment Type
9.3.1.2.4. By Targeted Antigen
9.3.1.2.5. By End User
9.3.2. Argentina CAR-T Cell Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1 By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tumor Type
9.3.2.2.2. By Indication
9.3.2.2.3. By Treatment Type
9.3.2.2.4. By Targeted Antigen
9.3.2.2.5. By End User

13. 13
© TechSci Research
Table of Contents
13
S. No. Contents
9.3.3. Colombia CAR-T Cell Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1 By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tumor Type
9.3.2.2.2. By Indication
9.3.2.2.3. By Treatment Type
9.3.2.2.4. By Targeted Antigen
9.3.2.2.5. By End User
10. Middle East & Africa CAR-T Cell Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tumor Type
10.2.2. By Indication
10.2.3. By Treatment Type
10.2.4. By Targeted Antigen
10.2.5. By End User
10.2.6. By Country

14. 14
© TechSci Research
Table of Contents
14
S. No. Contents
10.3. Middle East & Africa : Country Analysis
10.3.1. Israel CAR-T Cell Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tumor Type
10.3.1.2.2. By Indication
10.3.1.2.3. By Treatment Type
10.3.1.2.4. By Targeted Antigen
10.3.1.2.5. By End User
10.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tumor Type
10.3.2.2.2. By Indication
10.3.2.2.3. By Treatment Type
10.3.2.2.4. By Targeted Antigen
10.3.2.2.5. By End User

15. 15
© TechSci Research
Table of Contents
15
S. No. Contents
10.3.3. UAE CAR-T Cell Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tumor Type
10.3.3.2.2. By Indication
10.3.3.2.3. By Treatment Type
10.3.3.2.4. By Targeted Antigen
10.3.3.2.5. By End User
10.3.4. South Africa CAR-T Cell Therapy Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Tumor Type
10.3.4.2.2. By Indication
10.3.4.2.3. By Treatment Type
10.3.4.2.4. By Targeted Antigen
10.3.4.2.5. By End User

16. 16
© TechSci Research
Table of Contents
16
S. No. Contents
11. Impact of COVID-19 on Global CAR-T Cell Therapy Market
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends and Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2.1. Gilead Sciences, Inc
14.2.2. Novartis International AG
14.2.3. Bristol Myers Squibb Co.
14.2.4. AbbVie Inc.
14.2.5. Cellectis SA
14.2.6. Amgen Inc
14.2.7. Pfizer Inc.
14.2.8 Merck & Co. Inc.
14.2.9. Intellia Therapeutics Inc.
14.2.10. Poseida Therapeutics Inc
14.2.11. Johnson & Johnson
14.2.12. Allogene Therapeutics Inc
14.2.13. Autolus Therapeutics PLC
14.2.14. Humanigen, Inc.
14.2.15. Sangamo Therapeutics, Inc.
15. Strategic Recommendations
16. About Us & Disclaimer

17. Product Overview

18. 18
© TechSci Research
Scope of Report
Product of Interest (POI): CAR-T Cell Therapy
Review Period
2017 – 2020
Base Year
2021
Estimated Year
2022
Forecast Period
2023 – 2027
Year Range
CAR-T Cell Therapy or Chimeric Antigen Receptor Therapy is an evolving form of cell therapy
wherein the T-Cells of the immune system are genetically engineered and altered to target
cancer cells. This is basically a type of immunotherapy that modifies the patient's immune
system so that it becomes more effective in identifying and destroying cancer cells.
Market Segmentation
By Tumor Type
• Hematological Malignancies
• Solid Tumors
By End User
18
By Region
• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa
By Product Type
• YESCARTA (Axicabtagene
Ciloleucel)
• KYMRIAH (Tisagenlecleucel)
• TECARTUS (Brexucabtagene
Autoleucel)
• BREYANZI (Lisocabtagene
Maraleucel)
• ABECMA (Idecabtagene
Vicleucel)
• Others
By Indication
• Diffused Large B-Cell Lymphoma
(DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Others
• Hospitals
• Specialty Clinics
• Ambulatory Surgical
Centers
• Others
By Treatment Type
• Single Treatment
• Combination Treatment
By Targeted Antigen
• CD 19
• BCMA
• Others

19. 19
© TechSci Research
Product Overview
• The immune system is the human body’s natural defense against diseases and infection. The immune system is made up of many
cells that help the body fight against diseases and infections. Lymphocyte, a type of white blood cell, forms the major part of the
immune system. There are three types of lymphocytes:
 B Lymphocytes or B Cells: They produce antibodies to help the body fight against infection.
 T Lymphocytes or T Cells: They have several functions, including directly killing the infected body cells and helping B cells to
produce antibodies.
 Natural Killer Cells (NK Cells): They control different types of tumors and infections by directly attacking the infected cells and
eliminating viruses.
 Immunotherapy has emerged as an effective treatment option in fighting chronic diseases such as cancer. Immunotherapy
improves the body's overall ability to identify and kill cancer cells.
 CAR-T Cell Therapy is a new form of immunotherapy wherein T Cells are altered to specifically target the cancer cells. CAR-T Cell
Therapy begins at the healthcare facilities by collecting and harvesting blood cells from the patient through apheresis. The collected
cells are then taken to a laboratory or a pharmaceutical manufacturing facility, wherein they are genetically engineered. DNA is
introduced on the collected T Cells to produce chimeric antigen receptors (CARs) on the surface of the cells. CARs are proteins that
allow the T cells to recognize an antigen on targeted tumor cells. After this genetic alteration, the T Cells are known as Chimeric
Antigen Receptor or CAR T Cells. These engineered CAR T Cells are further multiplied in the laboratory and then frozen. The frozen
cells are then sent to the hospital or treatment center where the patient is being treated. The CAR T Cells are thawed at the
treatment center or hospital and then infused into the patient.
• At present, there are only 5 CAR-T Cell Therapies approved by the FDA. These include YESCARTA (Axicabtagene Ciloleucel),
KYMRIAH (Tisagenlecleucel), TECARTUS (Brexucabtagene Autoleucel), BREYANZI (Lisocabtagene Maraleucel), ABECMA
(Idecabtagene Vicleucel). However, CAR-T Cell therapies are made available to patients participating in a clinical trial for
indications or cancers other than the FDA (Food and Drug Administration)-approved indications.
19

20. Research Methodology

21. 21
© TechSci Research
Research Methodology
 Identifying Key Opinion
Leaders
 Questionnaire Design
 In-depth Interviews
Data
Collection
Developing list
of respondents
Formulating
Questionnaire
Market
Profiling
Data
Validation
Data
Analysis
In-depth secondary
research was conducted to
determine the overall
market size, segmental
market size and top
players in the Global CAR-T
Cell Therapy market.
In order to conduct
industry experts’
interviews, TechSci
formulated a detailed
discussion guide.
List of industry
players and industry
specialists was
developed.
TechSci conducted
interviews with
industry experts and
industry players for
data collection and
verification.
Data obtained as a
result of primary
and secondary
research was
validated through
rigorous
triangulation.
The data was scrutinized
using MS-Excel, statistical
tools and internal
proprietary database to
obtain qualitative and
quantitative insights about
the Global CAR-T Cell
Therapy market.
Data
Collection
Data Filter
& Analysis
Research &
Intelligence
Actionable
Insights
Business
Solution
Primary Research Desk Research Company Analysis
 Recent Developments
 Market Changing
Aspects/Dynamics
 Government Policies
 Final Conclusion
 Market Participants
 Key Strengths
 LinkedIn
 TechSci Internal
Database
 Factiva
 Hoovers
Paid Sources
 Company Websites
 Company Annual
Reports
 White Paper Study
 Financial Reports
 Investor
Presentations
 Regulatory Body
 Associations, etc.
Secondary
Research
Primary Research
21

22. 22
© TechSci Research
Research Methodology
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of the global CAR-T Cell Therapy market. The
team has analyzed the outlook of various segments of this market, while considering the major influencing factors such as growing
prevalence of cancer, growing popularity of precision medicine, among others. The study includes market forecasting, which would
enable our clients to take better decisions while planning their strategy to achieve sustainability in the global CAR-T Cell Therapy
market.
Methodology Followed for Calculation of Market Size:
• Market Size by Value : Market size, in terms of value, for the year 2021 was calculated based on information collected through
exhaustive secondary research and primary surveys, with various key opinion leaders/stakeholders, such as CAR-T Cell Therapy
companies, channel partners, end users, industry experts, and other industry participants.
• The team interviewed more than 15 CAR-T Cell Therapy companies, 100 end users and 10 industry experts and other value chain
stakeholders in the global CAR-T Cell Therapy market to obtain the overall market size between 2017 and 2021, which was
validated by the Delphi technique. Taking standard deviation into consideration, the market size was averaged out, to arrive at the
market size data during 2017-2021.
• Respondents were asked about the current and future market growth rates, market shares by product type, by tumor type, by
indication, by treatment type, by targeted antigen, by end user, by region and by company. Removing the outlier responses, the
geometric mean of growth estimates and category wise revenue shares generated across various segments were considered to
22

23. 23
© TechSci Research
Research Methodology
arrive at the final revenue shares. Revenue shares generated across various segments were further triangulated based on the
response received from other stakeholders.
Methodology Followed For Calculation of Market Shares:
• Market shares by product type, by tumor type, by indication, by treatment type, by targeted antigen, by end user, by region
and by company were calculated based on the responses received through primary surveys with industry experts, in which the
respondents were asked about the market shares or revenue generated from various segments of the global CAR-T Cell Therapy
market. The final shares were calculated by taking the geometric mean of the responses gathered from key opinion leaders after
eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey
results in SPSS/Tableau software. Data triangulation techniques were applied to fill the gaps and to present a more meaningful
picture of the market. To forecast the global CAR-T Cell Therapy market, TechSci Research used various forecast techniques
such as:
 Moving Average
 Time Series Analysis
 Regression Analysis
 Econometric and Judgmental Analysis
23
• Note:
(a) Sum of some shares may not be 100% due to round off till two decimal
places.
(b) The actual market data for 2021 is for nine months till September 2021.
For rest of three months between October 2021 and December 2021,
the data is estimated.

24. 24
© TechSci Research
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci
Research also used the impact analysis during short, medium and long term period to estimate the demand and to reach accurate
market numbers. The currency used in the report is the United States Dollar (with the market size indicated in USD million).
Partial List of Companies Interviewed Key Secondary Sources
 Gilead Sciences, Inc.
 Novartis International AG
 Bristol Myers Squibb Co.
 AbbVie Inc.
 Collectis SA
 Amgen Inc.
 Pfizer Inc.
 Merck & Co
 Intellia Therapeutics Inc.
 Poseida Therapeutics Inc.
 Johnson & Johnson
 Allogene Therapeutics Inc.
 Autolus Therapeutics Plc.
 Humanigen Inc
 Sangamo Therapeutics, Inc.
 World Bank
 TechSci Research Proprietary Database &
Knowledge Repository
 Company Annual Reports
 Industry Magazines
 Industry Reports
 Food and Drug Administration (FDA)
 Credible Paid Databases
 Centers for Disease Control and Prevention
 World Health Organization (WHO)
 Global Cancer Observatory (Globocan)
 National Cancer Institute
 Leukemia & Lymphoma Society
24

25. 25
© TechSci Research
Industry Brief
25
Increasing prevalence of different types of Cancer is driving the growth in Global CAR-T Cell Therapy market in the forecast period, 2022-2027.
According to TechSci Research report, “CAR-T Cell therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027”, the global CAR-T Cell therapy market stood at USD 1709.00 Million
in 2021 and is expected to grow at a CAGR of 64.66% during the forecast period on account of growing prevalence of different types of Cancer. The continuously approval of new CAR-T Cell therapies from different
companies is expected to support the market growth through 2027. The growing prevalence of various types of Cancer such as Diffused Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Multiple
Myeloma (MM), Breast Cancer, Acute Lymphoblastic Leukemia (ALL), and many others has significantly increased the patient pool worldwide suffering from these diseases. This in turn has significantly increased the
demand for various CAR-T Cell therapies. These CAR-T Cell therapies can be used for treatment of these types of Cancer. For Instance, in September 2021, China’s National Medical Products Administration
(NMPA) has approved its CAR-T cell immunotherapy of JW Therapeutics’ Relmacabtagene autoleucel injection by the brand name of relma-cel. Apart of that, increase in the number of CAR-T Cell Therapy Clinical
Studies also supporting the market growth of CAR-T Cell therapy market. For instance, 1304 ongoing or upcoming CAR-related trials registered at ClinicalTrials.gov as of December 22, 2020. Out of which total of 433
trials (56%) were from China and 288 from the US (37%). However, the high cost of CAR-T Cell Therapy leads to affordability constraints, especially in developing countries of Asia Pacific, South America, and Middle
East & Africa. Also, stringent regulatory scenario and policies for launching and marketing CAR-T Cell therapy are expected to significantly hamper the market growth. The FDA is very strict when it comes to the
approvals for them. Also, countries that do not follow FDA but have their own regulatory associations are also very strict for product approvals and their market launch. The regulatory framework is quite strict when it
comes to product recalls. Furthermore, lack of awareness pertaining to the availability and use of CAR-T Cell therapy among the population, especially in the developing and under-developed countries, is expected to
hamper the market growth during the forecast period.
The Global CAR-T Cell Therapy market is segmented based on by product type, tumor type, indication, treatment type, targeted antigen, end user, company, and regional distribution.
Based on product type, the market can be split into YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), TECARTUS (brexucabtagene autoleucel), BREYANZI (lisocabtagene maraleucel), ABECMA
(idecabtagene Vicleucel), and Others. YESCARTA (axicabtagene ciloleucel) dominates the market of CAR-T Cell therapy by accounting the share of 49.27% in 2021. This mainly due to the approval of Yescarta in
different Countries such as China, Japan, and others.
Based on tumor type, the market is divided into Hematological Malignancies and Solid Tumors. Hematological Malignancies dominates the market most of the CAR-T Cell therapy which get approved are used to
treat Hematological Malignancies.
Based on indication, the market can be divided into Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Others. Diffused
Large B-Cell Lymphoma (DLBCL) dominates the market followed by Acute Lymphoblastic Leukemia (ALL) as due to increase in the number of Diffused Large B-Cell Lymphoma (DLBCL) cases and mainly all
approved CAR-T Cell therapies are used to treat Lymphoma cancer.
In terms of treatment type, the market divided into Single Treatment and Combination Treatment. Based on targeted antigen, the market is segmented into CD 19, BCMA, and Others. In terms of end user, the market
is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others.
Key market players in the Global CAR-T Cell therapy market include Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc.,
Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc
Global CAR-T Cell therapy market is consolidated with a lot of well-established players having presence in several countries: with several domestic players possessing leadership in certain regions and countries,
among others. Gilead Sciences Inc. holds the highest market share and is among the top five market players globally. Novartis International AG ranks second in terms of market share in the overall CAR-T Cell
therapy market. The company has a strong presence worldwide and a huge Kymirah brand value. People in emerging countries are also aware about the presence, product portfolio and business of the company and
are preferring it over other competitor brands.
Additionally, there are other prominent players that are doing research relates to CAR-T Cell therapies such as AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida
Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc, and among others. For instances, Johnson & Johnson and partner Legend
Biotech are expecting an FDA decision for their first CAR-T product, cilta-cel.
“The North America dominates the market of CAR-T Cell therapy. This can be attributed to the large and growing cancer population in the region, which is susceptible to different kinds of cancers, especially in
countries like United States, Canada, and Mexico. Additionally, all the approved CAR-T Cell first approved by US-FDA which is expecting to support market growth. For instance, “all 5 FDA-approved commercial
CAR-T cell therapies are available in the United States. Also, an increasing number of healthcare and pharmaceutical companies are focusing on the development and commercial manufacturing of CAR T-cells in the
country and growing awareness and adoption of personalized treatments are expected to support the market growth through 2027,” said Mr. Karan Chechi, Research Director with TechSci Research, a research
based Global management consulting firm.

26. 26
© TechSci Research
Sample Data - Snapshot
26
Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
CAGR 2017-2021
By Value: xxx%
CAGR 2022E-2027F
By Value: xxx%
2017 2018 2019 2020 2021 2022E 2023F 2024F 2025F 2026F 2027F
Value (USD Million)
North America CAR-T Cell Therapy Market Share, By Tumor
Type, By Value, 2017-2027F
201
7
201
8
201
9
202
0
202
1
202
2E
202
3F
202
4F
202
5F
202
6F
202
7F
Hematological
Malignancies
40.040.040.040.040.040.040.040.040.040.040.0
Solid Tumors 60.060.060.060.060.060.060.060.060.060.060.0
United States CAR-T Cell Therapy Market Share, By
Treatment Type, By Value, 2017-2027F
201
7
201
8
201
9
202
0
202
1
202
2E
202
3F
202
4F
202
5F
202
6F
202
7F
Single Treatment40.00
40.00
40.00
40.00
40.00
40.00
40.00
40.00
40.00
40.00
40.00
Combination
Treatment
60.00
60.00
60.00
60.00
60.00
60.00
60.00
60.00
60.00
60.00
60.00
2017 2018 2019 2020 2021 2022E 2023F 2024F 2025F 2026F 2027F
Diffused Large B-cell Lymphoma 5.00% 5.00% 5.00% 5.00% 5.00% 5.00% 5.00% 5.00% 5.00% 5.00% 5.00%
Acute Lymphoblastic Leukemia 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00% 10.00%
Follicular Lymphoma 15.00% 15.00% 15.00% 15.00% 15.00% 15.00% 15.00% 15.00% 15.00% 15.00% 15.00%
Mantle Cell Lymphoma 20.00% 20.00% 20.00% 20.00% 20.00% 20.00% 20.00% 20.00% 20.00% 20.00% 20.00%
Others 50.00% 50.00% 50.00% 50.00% 50.00% 50.00% 50.00% 50.00% 50.00% 50.00% 50.00%
United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F

27. 27
© TechSci Research
Report Ordering
27
To View Sample OR Purchase Report
License Type Price
Single User License $4900
Multi-User License $5900
Custom Research License $8900
Report Name: GLOBAL OXYGEN CONCENTRATORS MARKET
FORECAST & OPPORTUNITIES
2016 – 2026

28. About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in
number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality
analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and global
company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the market.
Related Reports
• Cell Therapy Manufacturing Market, Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2016-2026 Segmented By
Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By
Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular
Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
• Global Regenerative Medicine Market, By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Others), By Application
(Musculoskeletal Disorders, Wound Care, Others), By Material (Synthetic Material, Biologically Derived Material, Others), By Cell (Autologous,
Allogenic), By Product (Biologic, Cell -based Medical Devices, Others), By Technique (Microfracture, Mosaicplasty), By Distribution Channel
(Hospitals, Clinics , Others), By Region & Opportunities, 2025
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely,
accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it
considers reliable and first hand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible
for any errors or omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the
subscribers / users of this report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this
document are indicative of relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior
approval of TechSci Research.
TechSci Research – North America
708 Third Avenue, Manhattan,
New York, United States
Tel: +1- 646- 360- 1656
Email: sales@techsciresearch.com
www.techsciresearch.com
Disclaimer
TechSci Research – Europe
54, Old brook, Bretton,
Peterborough,
United Kingdom
Email: sales@techsciresearch.com
www.techsciresearch.com
TechSci Research – Asia Pacific
B – 44, Sector – 57, Noida, National Capital
Region, U.P. - India
Tel: +91-120-4523900
Email: sales@techsciresearch.com
www.techsciresearch.com